AHA GUIDELINES Bundle (free trial)

Hypertrophic Cardiomyopathy 2024

AHA GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1521559

Contents of this Issue

Navigation

Page 25 of 43

26 Treatment Figure 3. Patient Selection for ICD Use An ICD is recommended (1) * ICD decisions in pediatric patients with HCM are based on ≥1 of these major risk factors: family history of HCM SCD, NSVT on ambulatory monitor, massive LVH, and unexplained syncope. † 5-Year risk estimates can be considered to fully inform patients during shared decision- making discussions. ‡ It would seem most appropriate to place greater weight on frequent, longer, and faster runs of NSVT. CMR indicates cardiovascular magnetic resonance; EF, ejection fraction; FH, family history; HCM, hypertrophic cardiomyopathy; ICD, implantable cardioverter-defibrillator; LGE, late gadolinium enhancement; LVH, le ventricular hypertrophy; NSVT, nonsustained ventricular tachycardia; SCD, sudden cardiac death; VF, ventricular fibrillation; and VT, ventricular tachycardia. NSVT * †‡ An ICD is reasonable (2a) An ICD may be considered (2b) An ICD is not indicated (3: Harm) NO NO NO NO Prior event (SCD, VF, sustained VT) YES YES YES YES Adults Extensive LGE on CMR Children At least 1 of the following: • FH SCD* • Massive LVH* • Unexplained syncope* • Apical aneurysm • EF <50% 5-Year risk estimate for shared decision- making (2a) 5-Year risk estimate for shared decision- making (2a)

Articles in this issue

Archives of this issue

view archives of AHA GUIDELINES Bundle (free trial) - Hypertrophic Cardiomyopathy 2024